late onset depression Mild cognitive impairment
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Informed consent • Aged between 50-80 years • Assigned by physician as competent to participate in the study • Inclusion groups: o Fulfilling the criteria for healthy volunteers o Fulfilling the criteria for late onset depression o Fulfilling the criteria for MCI o Fulfilling the criteria for both late onset depression and MCI
Exclusion criteria
Exclusion criteria: • History of major psychiatric disorders such as schizophrenia and bipolar disorder and previous unipolar depression • History of head trauma • Ischemic cerebrovascular disease, determined by MRI • Major medical illnesses such as coronary heart disease, diabetes and cancer • Chronic inflammatory disease such as rheumatoid arthritis, osteoarthritis, chronic obstructive pulmonary disease, psoriasis, etc. • Use of anti-inflammatory medication such as non-steroidal anti-inflammatory drugs (NSAID) and corticosteroids during a week before PET scan • The use benzodiazepines a week before the PET scan • The use of statins, acetylcholinesterase inhibitors, warfarin and digoxin • History of substance abuse such as alcohol and nicotine (smoking) within the last 6 months • Presence of dementia • Any patients with MRI contradictions such as metal implantations and pacemakers • Malnutrition (vitamin deficiency) or obesity (BMI > 30)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quantification of alterations of brain beta-amyloid and activated microglia on the progress of dementia in patients with mild cognitive impairment and late onset depression determined with PET. | — |
Secondary
| Measure | Time frame |
|---|---|
| • Plasma pro-inflammatory proteins as well as brain derived neurotrophic factor. • Cognition. • Alterations in brain volume | — |
Countries
Netherlands
Outcome results
None listed